As we continue to unlock the therapeutic power of microbiome science, don’t miss opportunities within this vital sector that will hugely impact our industry — and the lives of patients living with chronic disease.
Microbiome science is changing medicine and will transform the treatment of chronic disease. Research into the microbiome and modulation of the community of bacteria in the human body and environment continues to emerge at record rates.
From discovery to transactions, we support biopharmaceutical companies in the microbiome space to ensure they are maximizing their potential in this evolving field and dynamic marketplace. We also frequently advise private equity investors and venture capital firms on individual assets, companies and help them assess value and evaluate therapeutic assets and platforms. Our experienced team can advise on:
- Sale, Lease and Purchase of Laboratory and Manufacturing Facilities
- Sourcing Mandates
- Carve Outs and Divestments
- Corporate M&A Transactions
- Investment Diligence
- Manufacturing Capacity Evaluation